enbucrilate has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alyautdin, RN; Balabanian, VY; Kapica, IG; Kreuter, J; Kurakhmaeva, KB; Nerobkova, LN; Seredenin, SB; Voronina, TA | 1 |
| Alyautdin, RN; Balabanyan, VU; Begley, D; Djindjikhashvili, IA; Gelperina, S; Kreuter, J; Kurakhmaeva, KB; Petrov, VE; Trofimov, SS; Voronina, TA | 1 |
2 other study(ies) available for enbucrilate and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Antiparkinsonian effect of nerve growth factor adsorbed on polybutylcyanoacrylate nanoparticles coated with polysorbate-80.
Topics: Adsorption; Animals; Antiparkinson Agents; Blood-Brain Barrier; Drug Carriers; Enbucrilate; Male; Mice; Mice, Inbred C57BL; Motor Activity; Nanoparticles; Nerve Growth Factor; Parkinsonian Disorders; Polysorbates; Surface-Active Agents | 2008 |
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
Topics: Amnesia; Animals; Biological Transport; Blood-Brain Barrier; Brain; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Enbucrilate; Injections, Intravenous; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Nerve Growth Factor; Parkinsonian Disorders; Polysorbates; Rats | 2009 |